Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis
NCT ID: NCT00043316
Last Updated: 2007-11-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
66 participants
INTERVENTIONAL
2001-02-28
2002-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The FDA has not approved Interferon gamma-1b for use with cystic fibrosis patients, which is the condition being examined in this study.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
QUADRUPLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
interferon gamma-1b
500 or 1000 mcg, inhalation, 3x per week
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of cystic fibrosis with mild to moderate pulmonary impairment
* Must be receiving ongoing chronic treatment with TOBI (inhaled tobramycin) OR not receiving ongoing chronic treatment with TOBI and no use of TOBI or other inhaled antibiotic within 4 weeks prior to study drug administration·
* Other specific diagnostic indicators of CF and other factors must meet minimum requirements.
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
InterMune
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Steve Porter, MD
Role: STUDY_DIRECTOR
InterMune
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham, Alabama, United States
Phoenix, Arizona, United States
Palo Alto, California, United States
Sacramento, California, United States
San Diego, California, United States
San Francisco, California, United States
Denver, Colorado, United States
Daytona Beach, Florida, United States
Orlando, Florida, United States
Chicago, Illinois, United States
New Orleans, Louisiana, United States
Rochester, Minnesota, United States
New York, New York, United States
Philadelphia, Pennsylvania, United States
Nashville, Tennessee, United States
Lackland Air Force Base, Texas, United States
Tyler, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GICF-001
Identifier Type: -
Identifier Source: org_study_id